via Livemint.com
In a new study assessing the potential of a single-dose, intranasal COVID-19 vaccine, a team from the University of Iowa and the University of Georgia found that the vaccine fully protects mice against lethal COVID-19 infection. The vaccine also blocks animal-to-animal transmission of the virus.
The findings were published July 2 in the journal Science Advances.
“The currently available vaccines against COVID-19 are very successful, but the majority of the world’s population is still unvaccinated and there is a critical need for more vaccines that are easy to use and effective at stopping disease and transmission,” says Paul McCray, MD, professor of pediatrics-pulmonary medicine, and microbiology and immunology at the UI Carver College of Medicine, and co-leader of the study. “If this new COVID-19 vaccine proves effective in people, it may help block SARS-CoV-2 transmission and help control the COVID-19 pandemic.”
Unlike traditional vaccines that require an injection, this vaccine is administered through a nasal spray similar to those commonly used to vaccinate against influenza. The vaccine used in the study only requires a single dose and it may be stored at normal refrigerator temperatures for up to at least three months. Because it is given intranasally, the vaccine may also be easier to administer, especially for those who have a fear of needles.
“We have been developing this vaccine platform for more than 20 years, and we began working on new vaccine formulations to combat COVID-19 during the early days of the pandemic,” says Biao He, PhD, a professor in the University of Georgia’s Department of Infectious Diseases in the College of Veterinary Medicine and co-leader of the study. “Our preclinical data show that this vaccine not only protects against infection, but also significantly reduces the chances of transmission.”
The experimental vaccine uses a harmless parainfluenza virus 5 (PIV5) to deliver the SARS-CoV-2 spike protein into cells where it prompts an immune response that protects against COVID-19 infection. PIV5 is related to common cold viruses and easily infects different mammals, including humans, without causing significant disease. The research team has previously shown that this vaccine platform can completely protect experimental animals from another dangerous coronavirus disease called Middle Eastern Respiratory Syndrome (MERS).
The inhaled PIV5 vaccine developed by the team targets mucosal cells that line the nasal passages and airways. These cells are the main entry point for most SARS-CoV-2 infections and the site of early virus replication. Virus produced in these cells can invade deeper into the lungs and other organs in the body, which can lead to more severe disease. In addition, virus made in these cells can be easily shed through exhalation allowing transmission from one infected person to others.
Original Article: Inhaled COVID-19 vaccine prevents disease and transmission in animals
More from: University of Iowa | University of Georgia
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Inhalable Covid-19 vaccine
- New prototype that regenerates stem cells may repair IPF scarring
Researchers developed NZ-97, an inhalable drug that stimulates the growth of stem cells in the lungs, potentially repairing scarring in IPF.
- Undocumented Latinx patients got COVID-19 vaccine at same rate as US citizens, study finds
For undocumented Latinx patients who sought care in the emergency room during the pandemic, the reported rate of having received the COVID-19 vaccine was found to be the same as U.S. citizens, a new ...
- Psychiatric Disorders Do Not Decrease COVID-19 Vaccine Effectiveness
Researchers conducted a retrospective cohort analysis to evaluate the effectiveness of COVID-19 vaccination among US adults with common psychiatric disorders.
- Study confirms effectiveness of bivalent COVID-19 vaccine
A major bivalent COVID-19 vaccine induces production of neutralizing antibodies against the coronavirus that circulated at the start of the pandemic as well as subvariants of omicron, albeit less ...
- Updated Alberta Covid-19 vaccine advice misrepresented online
Alberta announced new Covid-19 vaccination guidelines, but social media posts and articles claiming the Canadian province is now recommending a new shot every three months are misleading. Only ...
Go deeper with Google Headlines on:
Inhalable Covid-19 vaccine
[google_news title=”” keyword=”inhalable Covid-19 vaccine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Inhalable vaccines
- COVID and SARS News
Apr. 1, 2024 — Researchers have developed a new vaccine that offers broad protection against not only SARS-CoV-2 variants, but also other bat sarbecoviruses. The groundbreaking trivalent vaccine ...
- Why Are Pharmaceutical Companies Gradually Abandoning Vaccines?
Recent vaccine shortages are not coincidental, nor do they represent short-lived, easily fixable problems in the vaccine industry. Rather, several market forces explain why pharmaceutical ...
- The Evolving History of Influenza Viruses and Influenza Vaccines
The first influenza vaccine was a monovalent live-attenuated vaccine, which was used in Russia until recently. In 1940, a second strain of influenza virus was isolated; this was named influenza B ...
- VBIV VBI Vaccines Inc.
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV ...
- Vaccines News
Mar. 12, 2024 — Researchers have highlighted the importance of continued surveillance of emerging SARS-CoV-2 variants and vaccine performance as the virus continues to ... Optimizing Boosters ...
Go deeper with Google Headlines on:
Inhalable vaccines
[google_news title=”” keyword=”inhalable vaccines” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]